Kazia Therapeutics - ADR Key Ratios
$12.31
$0.15
(1.23%)
As on 04-Sep-2026 17:30EDT
Market cap
$141 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -98.18 | 61.34 | -46.83 |
| EBIT | -- | -- | 50.05 | 12.92 | -3.56 |
| Net Profit | -23.83 | -17.87 | 22.69 | 5.44 | -19.43 |
| EPS | 38.35 | 67.88 | 56.39 | -618.97 | -290.24 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Jun-25 | Jun-24 | Jun-23 |
| EBIT-Margin
| -1,461,936.26 | -927,938.15 | -33,850.00 | -1,233.19 | -4,350,725.59 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -847.76 | -532.96 | 226.03 | -2,634.33 | -134.97 |
| Return on Capital
| -360.34 | -239.95 | 239.50 | -1,200.00 | -120.52 |
| Return on Assets
| -107.19 | -79.11 | -149.76 | -107.83 | -63.98 |
| Debt to Equity (x)
| -- | -- | -0.05 | -0.06 | 0.15 |
Profitability
ROCE
239.50
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
239.50
|
-1,200.00
|
-120.52
|
-86.30
|
-32.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
226.03
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
226.03
|
-2,634.33
|
-134.97
|
-89.14
|
-32.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-149.76
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
-149.76
|
-107.83
|
-63.98
|
-53.23
|
-20.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-33,850.00
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
-33,850.00
|
-1,233.19
|
-4,350,725.59
|
-253,840.00
|
-41.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-49,290.48
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
-49,290.48
|
-1,160.23
|
-3,687,419.82
|
-250,140.00
|
-55.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-0.98
--
Year on year growth in net sales
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
-0.98
|
4,157.56
|
-0.94
|
-1.00
|
14.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
50.05
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
50.05
|
-17.87
|
4.88
|
-298.12
|
47.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
22.69
--
Year on year growth in profit after tax
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
22.69
|
-30.85
|
18.19
|
-197.08
|
32.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.56
--
Year on year growth in earnings per share
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
0.56
|
-643.78
|
0.50
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.05
--
Total debt / Net worth
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
-0.05
|
-0.06
|
0.15
|
0.10
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.05
--
(Short term borrowings / Net worth)
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
-0.05
|
-0.06
|
0.15
|
0.10
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.35
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
0.35
|
0.24
|
1.42
|
1.40
|
3.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
--
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
--
|
--
|
1.93
|
--
|
3.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
--
|
--
|
--
|
-12,122.25
|
-1.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
214.29
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
214.29
|
5.76
|
18,918.92
|
510.00
|
0.50
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.00
--
Sales / Average Total Assets
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
0.00
|
0.09
|
0.00
|
0.00
|
0.37
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
969.65
--
Average Debtors / Sales * 365
|
Company Name
|
Jun-25
|
Jun-24
|
Jun-23
|
Jun-22
|
Jun-21
|
|---|---|---|---|---|---|
|
Kazia Therapeutics - ADR
|
969.65
|
18.83
|
51,332.43
|
2,319.34
|
0.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
